Leveraging emerging global markets

Globalization is one of the most significant trends impacting the biopharmaceutical industry today.  This trend is driven by several factors, including:

• The dramatic growth and vast sales potential for biopharmaceutical products in emerging global markets
• Patient recruitment challenges for clinical trials in North America and Western Europe, combined with the need to access larger numbers of patients and qualified investigators for expanded Phase III and Phase IV trials
• The need to reduce development expenses by taking advantage of high-quality, lower-cost clinical resources around the world
• Pressure to maximize portfolio value and increase return on investment by introducing new products in as many markets as possible

In order to maximize these opportunities in emerging regions, sponsors must have the right strategic partner – a partner with global clinical resources…extensive databases of pre-qualified patients and investigators…regional regulatory and marketing experience…the ability to maintain quality and data integrity across multinational trials…and in-depth understanding of local medical practices and cultural issues.

With offices in 54 countries, PAREXEL is right where you need us to support your biopharmaceutical development programs anywhere in the world.  Our extensive global experience encompasses all the emerging regions of the world, including Central and Eastern Europe, Latin America, Africa, India, the Middle East, and the Asia/Pacific region.  We can provide access to diverse patient populations to speed recruitment, well-qualified investigators across every therapeutic category to accelerate trial start-ups, and regulatory expertise to speed market access for your products in multiple countries.  Most important, PAREXEL has conducted more than 60,000 studies in 157 countries, giving us unique insight to meet your clinical, regulatory, and marketing requirements around the world. 

Click Image to Enlarge

With PAREXEL’s global connections, our partners can take advantage of the opportunities in emerging regions to expand their global clinical development programs, lower the cost of conducting clinical research, and bring new therapies more quickly to patients around the world.

Click here for more information about PAREXEL’s resources in specific emerging markets.